tetano
Editor, Senior Moderator
NPJ Vaccines
. 2024 May 31;9(1):97.
doi: 10.1038/s41541-024-00891-3. Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge
M N Pascha[SUP] #[/SUP][SUP] 1 [/SUP], M Ballegeer[SUP] #[/SUP][SUP] 2 3 [/SUP], M C Roelofs[SUP] 4 [/SUP], L Meuris[SUP] 2 3 [/SUP], I C Albulescu[SUP] 1 [/SUP], F J M van Kuppeveld[SUP] 1 [/SUP], D L Hurdiss[SUP] 1 [/SUP], B J Bosch[SUP] 1 [/SUP], T Zeev-Ben-Mordehai[SUP] 4 [/SUP], X Saelens[SUP] 5 6 [/SUP], C A M de Haan[SUP] 7 [/SUP]
Affiliations
Current Influenza virus vaccines primarily induce antibody responses against variable epitopes in hemagglutinin (HA), necessitating frequent updates. However, antibodies against neuraminidase (NA) can also confer protection against influenza, making NA an attractive target for the development of novel vaccines. In this study, we aimed to enhance the immunogenicity of recombinant NA antigens by presenting them multivalently on a nanoparticle carrier. Soluble tetrameric NA antigens of the N1 and N2 subtypes, confirmed to be correctly folded by cryo-electron microscopy structural analysis, were conjugated to Mi3 self-assembling protein nanoparticles using the SpyTag-SpyCatcher system. Immunization of mice with NA-Mi3 nanoparticles induced higher titers of NA-binding and -inhibiting antibodies and improved protection against a lethal challenge compared to unconjugated NA. Additionally, we explored the co-presentation of N1 and N2 antigens on the same Mi3 particles to create a mosaic vaccine candidate. These mosaic nanoparticles elicited antibody titers that were similar or superior to the homotypic nanoparticles and effectively protected against H1N1 and H3N2 challenge viruses. The NA-Mi3 nanoparticles represent a promising vaccine candidate that could complement HA-directed approaches for enhanced potency and broadened protection against influenza A virus.
. 2024 May 31;9(1):97.
doi: 10.1038/s41541-024-00891-3. Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge
M N Pascha[SUP] #[/SUP][SUP] 1 [/SUP], M Ballegeer[SUP] #[/SUP][SUP] 2 3 [/SUP], M C Roelofs[SUP] 4 [/SUP], L Meuris[SUP] 2 3 [/SUP], I C Albulescu[SUP] 1 [/SUP], F J M van Kuppeveld[SUP] 1 [/SUP], D L Hurdiss[SUP] 1 [/SUP], B J Bosch[SUP] 1 [/SUP], T Zeev-Ben-Mordehai[SUP] 4 [/SUP], X Saelens[SUP] 5 6 [/SUP], C A M de Haan[SUP] 7 [/SUP]
Affiliations
- PMID: 38821988
- PMCID: PMC11143307
- DOI: 10.1038/s41541-024-00891-3
Current Influenza virus vaccines primarily induce antibody responses against variable epitopes in hemagglutinin (HA), necessitating frequent updates. However, antibodies against neuraminidase (NA) can also confer protection against influenza, making NA an attractive target for the development of novel vaccines. In this study, we aimed to enhance the immunogenicity of recombinant NA antigens by presenting them multivalently on a nanoparticle carrier. Soluble tetrameric NA antigens of the N1 and N2 subtypes, confirmed to be correctly folded by cryo-electron microscopy structural analysis, were conjugated to Mi3 self-assembling protein nanoparticles using the SpyTag-SpyCatcher system. Immunization of mice with NA-Mi3 nanoparticles induced higher titers of NA-binding and -inhibiting antibodies and improved protection against a lethal challenge compared to unconjugated NA. Additionally, we explored the co-presentation of N1 and N2 antigens on the same Mi3 particles to create a mosaic vaccine candidate. These mosaic nanoparticles elicited antibody titers that were similar or superior to the homotypic nanoparticles and effectively protected against H1N1 and H3N2 challenge viruses. The NA-Mi3 nanoparticles represent a promising vaccine candidate that could complement HA-directed approaches for enhanced potency and broadened protection against influenza A virus.